Metsera accepted a sweetened offer from Pfizer late on Friday, citing U. S. antitrust risks in Novo’s bid that it had previously called superior.
Metsera accepted a sweetened offer from Pfizer late on Friday, citing U. S. antitrust risks in Novo’s bid that it had previously called superior.